FDA Approves Baxfendy for Uncontrolled Hypertension

The approval makes baxdrostat the first aldosterone synthase inhibitor available for adults whose blood pressure remains uncontrolled on existing treatments.

Updated on Nov. 19, 2026 in Healthcare

Smooth amber glass vessel beside a coiled blood pressure cuff on a pale surface under soft daylight, suggesting a new hypertension treatment.
The U.S. Food and Drug Administration approved AstraZeneca's Baxfendy, baxdrostat, in May 2026 for adults whose blood pressure stays uncontrolled on existing treatments. AI Illustration. Upload story photo >

Live Poll

Would you trust a new blood pressure medication if your doctor recommended it?

The U.S. Food and Drug Administration approved AstraZeneca's Baxfendy (baxdrostat) in May 2026 for adults with hypertension inadequately controlled by existing treatments. It is the first approved aldosterone synthase inhibitor.

Why it matters

The approval gives clinicians a new mechanism for patients whose blood pressure stays high despite current medications. Separate Phase 2 findings showing reduced urinary albumin in kidney disease patients point to possible benefits beyond blood pressure control, though larger trials are still testing this.

In the Phase 2 FigHTN trial of 192 patients with chronic kidney disease, urinary albumin fell 55% versus placebo, but elevated blood potassium occurred in 41% of baxdrostat recipients compared with 5% on placebo. Long-term safety in broader populations has not been established by the reported trials.

The players

AstraZeneca

A British-Swedish multinational pharmaceutical company headquartered in Cambridge, England, that developed baxdrostat and markets Baxfendy.

University College London

A public research university in London whose investigators led the kidney disease trial's research.

University of Utah Health

The academic health system of the University of Utah, whose researchers served as lead authors on the kidney disease study.

The details

Baxdrostat works by inhibiting the enzyme that produces aldosterone, a hormone regulating sodium and water balance, rather than blocking the hormone's receptors. Excess aldosterone causes the kidneys to retain fluid, raising blood pressure and potentially contributing to kidney inflammation and scarring.

Timeline

  1. September 6, 2025: The Journal of the American Society of Nephrology published findings from the kidney disease trial.

  2. May 2026: The FDA approved Baxfendy for uncontrolled hypertension.

Market Landscape

Baxfendy enters a hypertension market long dominated by receptor-blocking drugs such as spironolactone, positioning AstraZeneca to compete on a new mechanism. Its approval as the first aldosterone synthase inhibitor marks a departure from that established class.

Adults with hypertension that remains uncontrolled on current medications now have a prescription option with a new mechanism. Clinicians will weigh its potential for elevated blood potassium, which affected 41% of kidney disease trial recipients, when deciding whether it fits a patient's needs.

The takeaway

Newer hypertension drugs increasingly target the biological pathways behind high blood pressure rather than only symptoms. Patients on uncontrolled treatment should discuss with their clinicians whether a new mechanism could be an option.

What happens next

Two large Phase 3 trials are testing whether baxdrostat delays kidney disease progression, with results pending.

Further reading

Explore more on Healthcare developments shaping how new hypertension drugs reach patients.

Source note: This article includes information reported by SciTechDaily.

Live Poll

Would you trust a new blood pressure medication if your doctor recommended it?